#151839

Antitumoral Phortress Small Molecule (Tool Compound)

Please Enter Your Email ID
Email ID

Cat. #151839

Antitumoral Phortress Small Molecule (Tool Compound)

Cat. #: 151839

Sub-type: Antitumoral

Availability: Please enquire for quantities and pricing

Application: Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Malcolm F G Stevens

Institute: University of Nottingham

Tool Details
Handling
Target Details
Application Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: Antitumoral Phortress Small Molecule (Tool Compound)
  • Cancer: Breast cancer;Genitourinary cancer;Gynaecologic cancer
  • Cancers detailed: Breast cancer;Ovarian;Renal
  • Research fields: Cancer;Cell biology;Genetics
  • Molecular formula: C20H25Cl2FN4OS
  • Tool sub type: Antitumoral
  • Primary target: Human derived carcinomas of breast, ovarian and renal origin
  • Description: The Antitumoral Phortress compound is a potential anticancer agent for treatment of human breast carcinoma. Phortress is highly selective for susceptible cancer cells because of its mechanism of action. Following the release of 5F 203 from Phortress, it activates AhR signalling and causes induction of cytochrome P450 activity, which metabolically bioactivates 5F 203 to a cytotoxic species at the tumour site.Phortress (the dihydrochloride salt of the lysylamide prodrug of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203)) is an experimental antitumour agent with potent and selective activity against human-derived carcinomas of breast, ovarian and renal originThe mechanism of action of Phortress is distinct from all classes of chemotherapeutic agents currently in the clinic, and involves metabolic activation by cytochrome P450 (CYP) 1A1 to electrophilic species, which generate DNA adducts in sensitive tumours only.
  • Application: Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.
  • Molecular weight: 459.41
  • Additional notes: Compound available for screening or similar studies. For larger quantities (>20mg) please contact Ximbio. Product Documents: Phortress Diode Array Phortress NMR <a href="https://koi-3QNH6P8D7I.marketingautomati...

Handling

  • Purity: 459.41 g/mol
  • Shipping conditions: Dry Ice

Target Details

  • Primary target: Human derived carcinomas of breast, ovarian and renal origin
  • Ic50: IC50 values for MCF-7 and MDA468 cells are 40 nM and 158 nM, respectively

Application Details

  • Application: Active against breast, ovarian and renal carcinomas. Taken up into sensitive cells followed by aryl hydrocarbon receptor binding and translocation into the nucleus. Requires metabolic activation by cytochrome P450 to generate cytotoxic species. Induces expression of CYP1A1 and generates adducts in the DNA of sensitive MCF7 and IGROV-1 cells.

References

  • Bradshaw et al. 2009. Pharmacology. 83(2):99-109. PMID: 19088497.
  • Preclinical toxicokinetic evaluation of phortress [2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species.
  • Fichtner et al. 2004. Breast Cancer Res Treat. 87(1):97-107. PMID: 15377855.
  • The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models.
  • Bradshaw et al. 2004. Curr Med Chem. 11(8):1009-21. PMID: 15078...